Avidin
- Generic Name
- Avidin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 110539-97-4
- Unique Ingredient Identifier
- 639T22V8VD
- Background
Avidin is under investigation in clinical trial NCT00345618 (Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach).
- Associated Conditions
- -
- Associated Therapies
- -
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
- First Posted Date
- 2007-12-24
- Last Posted Date
- 2016-03-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3773
- Registration Number
- NCT00580216
- Locations
- ๐บ๐ธ
Sanofi-Aventis Investigational Site Number 840128, Philadelphia, Pennsylvania, United States
๐บ๐ธSanofi-Aventis Investigational Site Number 840181, Pittsburgh, Pennsylvania, United States
๐บ๐ธSanofi-Aventis Investigational Site Number 840146, Cleveland, Ohio, United States
Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach
- First Posted Date
- 2006-06-28
- Last Posted Date
- 2016-03-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3202
- Registration Number
- NCT00345618
- Locations
- ๐ท๐บ
Sanofi-Aventis Admnistrative Office, Moscow, Russian Federation
๐ฌ๐งSanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
๐ฆ๐บsanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia
Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs
- Conditions
- Interventions
- First Posted Date
- 2006-04-05
- Last Posted Date
- 2016-03-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 757
- Registration Number
- NCT00311090
- Locations
- ๐ท๐บ
Sanofi-aventis, Moscow, Russian Federation
๐ฒ๐ฝsanofi-aventis Mexico, Mexico, Mexico
๐น๐ทsanofi-aventis Turkey, Istanbul, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.